Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
How Has The Visceral Leishmaniasis Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In the past few years, the market for visceral leishmaniasis has seen significant growth. The market which is expected to be at $1.00 billion in 2024 is projected to grow to $1.06 billion in 2025, representing a compound annual growth rate (CAGR) of 6.1%. This increase during the historical period can be linked to a rising disease load, heightened government funding, the launch of amphotericin B, the refinement of miltefosine, a surge in awareness initiatives, enhanced access to healthcare in areas of high incidence, along with the formation of public-private collaborations.
In the upcoming years, the market for visceral leishmaniasis is predicted to experience robust growth, expanding to $1.33 billion in 2029 with a compound annual growth rate (CAGR) of 5.8%. This upward trend in the forecast period can be credited to a rise in vaccine development investment, improvements in global disease monitoring programs, the growth of public-private partnerships, increased funding towards neglected tropical diseases and progress in the field of gene-based therapies. Key trends expected during this forecast period encompass gene editing through clustered regularly interspaced short palindromic repeats (CRISPR), AI-enabled drug discovery, advancements in nanotechnology for drug delivery, parasite analysis using next-generation sequencing, wearable biosensors for early disease detection, use of blockchain in managing medical supply chains, smartphone-enabled diagnostic aids, and 3D bioprinting for individualized treatment research.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp
Which Primay Drivers Are Accelerating Growth in the Visceral Leishmaniasis Market?
The increase in malnutrition levels is predicted to boost the expansion of the visceral leishmaniasis market. Malnutrition, a health disorder resulting from insufficient or imbalanced consumption of necessary nutrients, compromises the body’s proper functioning. This rise in malnutrition stems from food insecurity, which restricts access to nutritious food, causing undernourishment and a lack of essential micronutrients that bolster the immune system. As malnutrition hampers immune function, it renders the body more susceptible to infections like visceral leishmaniasis. Shortage of nutrients debilitates the body’s defense system, heightening the probability of severe illness and complications. For example, in July 2024, the Food and Agriculture Organization, a specialized agency of the United Nations based in Italy, reported that the number of undernourished individuals escalated to 723.8 million in 2022 from 708.7 million in 2021. As such, the escalation in malnutrition is fueling the growth of the visceral leishmaniasis market.
Which Primary Segments of the Visceral Leishmaniasis Market Are Driving Growth and Industry Transformations?
The visceral leishmaniasis market covered in this report is segmented –
1) By Treatment: Antiparasitic, Antifungal, Other Treatments
2) By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods
3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Antiparasitic: Pentavalent Antimonials, Miltefosine, Paromomycin, Sitamaquine, Combination Therapy
2) By Antifungal: Amphotericin B, Liposomal Amphotericin B (AmBisome), Azoles, Echinocandins, Polyenes
3) By Other Treatments: Immunotherapy, Monoclonal Antibodies, Vaccine-Based Approaches, Photodynamic Therapy, Gene Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23573&type=smp
Which Regions Are Key Players in the Growth of the Visceral Leishmaniasis Market?
North America was the largest region in the visceral leishmaniasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Visceral Leishmaniasis Market?
Big firms in the visceral leishmaniasis market are concentrating on producing innovative treatment solutions, such as antiparasitic medications, to enhance effectiveness and expand patient accessibility, especially in areas where the disease is prevalent. Antiparasitic drugs, which are deployed to treat parasite-borne infections, aim at the parasite’s biological processes, thwarting its growth, reproduction, and survival in the host body. For instance, in February 2024, Zydus Lifesciences Limited, a pharmaceutical firm based in India, secured prequalification approval from the World Health Organization (WHO) for the active pharmaceutical ingredient (API) and composition of miltefosine, used to treat leishmaniasis or kala-azar. Miltefosine is an orally administered antiparasitic medication that causes parasite cell death by disturbing the parasite’s cell membrane and interfering with its metabolism. Additionally, it curbs parasite growth and survival, positioning it as an effective oral treatment solution for visceral leishmaniasis or kala azar.
View the full report here:
https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report
What Parameters Are Used to Define the Visceral Leishmaniasis Market?
Visceral leishmaniasis, also known as kala-azar, is a severe parasitic disease caused by Leishmania species, transmitted through infected sandfly bites. It affects internal organs such as the spleen, liver and bone marrow, causing prolonged fever, weight loss, anemia and organ enlargement. If untreated, it can be fatal, making early diagnosis and treatment crucial.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23573
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model